Establishment of brain natriuretic peptide ‐ based criteria for evaluating cardiac response to treatment in light chain (AL) amyloidosis

Summary Severity of cardiac involvement remains the leading determinant of survival in light chain (AL) amyloidosis. Until recently, cardiac response after treatment relied on reduction of N‐terminal pro‐brain natriuretic peptide (NT‐proBNP). In this study, 94 patients with AL amyloidosis (baseline BNP ≥150 pg/ml) had BNP measured at 6 months following treatment. Median overall survival was not reached for cardiac response (≥50 pg/ml and ≥ 30%...